A dysbalance between effector T cells (Tconv) and regulatory T cells (Tregs) and impaired Treg function can cause autoimmune liver disease. Therefore, it is important to identify molecular mechanisms that control Treg homeostasis. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1; CD66a) is an immune coreceptor with dichotomous roles in T-cell regulation: its short isoform (CEACAM1S) can activate T cells and induce Tregs, whereas its long isoform (CEACAM1L), containing two intracellular immune receptor tyrosine-based inhibitory motifs, can inhibit activated T-cell function. In the liver, CEACAM1 has antifibrotic effects in models of nonalcoholic steatohepatitis. However, its role in immune-mediated hepatitis is unknown. In the mouse model of concanavalin A-induced CD4
injury, liver damage was aggravated and persisted in Ceacam1 T -cell-mediated liver diseases, such as autoimmune hepatitis (AIH), (1) primary biliary cholangitis (PBC), (2) and primary sclerosing cholangitis (PSC), (3) result from loss of hepatic tolerance and lead to chronic inflammation and liver fibrosis. (4, 5) In autoimmune liver disease, autoreactive CD4 1 T cells induce immune-mediate liver injury, such as in AIH. The progressive dysbalance between conventional T cells (Tconv) and regulatory T cells (Tregs) is a hallmark of autoimmune diseases.
Contrarily, immune suppression occurs in the state of disease remission. Induction, expansion, and survival of functional immune-suppressive Tregs is therefore a critical determinant in disease progression and activity. To understand the molecular mechanisms that control these processes is pivotal for therapy development for autoimmune liver diseases. Hepatic tolerance induction comprises the conversion of Tregs from na€ ıve T cells by liver-resident nonprofessional antigen-presenting cells, such as hepatocytes (6, 7) and liver sinusoidal endothelial cells, (8) and the creation of a permissive cytokine micromilieu with sufficient intrahepatic interleukin (IL)-2 and transforming growth factor beta (TGFb) levels to induce CD4 1
Foxp3
1 (forkhead box protein P3 1 ) Tregs. (6, (9) (10) (11) Importantly, interlukin (IL)-2, and IL-2-mediated signal transducer and activator of transcription 5 (STAT5) signaling are fundamental for hepatic Treg survival and Treg homeostasis.
(1) STAT5 signaling is required for the transcription of Treg functional markers Foxp3, CD25, and cytotoxic Tlymphocyte associated protein 4 (CTLA-4), which determine Treg stability, survival, and suppressive function. (12) As such, hepatic IL-2 deficiency may compromise Treg conversion, resulting in imbalanced Treg homeostasis that favors effector T-cell responses and, ultimately, autoimmunity. (1) This is supported by identification of polymorphisms of the human highaffinity IL-2 receptor alpha chain (CD25) in patients with PSC that are associated with a reduction of FOXP3 1 Tregs from peripheral blood. (3) However, only limited data are available regarding a role of immune coreceptors modulating the IL-2/Tregs axis.
Expression of the cellular adhesion molecule carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) was first described on rat hepatocytes. (13) There, it plays a critical role in the regulation of hepatic metabolic function, given that CEACAM1-deficient mice develop nonalcoholic steatohepatitis when fed a high-fat diet. (14) Hepatic overexpression of CEACAM1 protects from hepatic fibrosis and inflammation. (15) Moreover, CEACAM1 is an immune coreceptor expressed by T cells, natural killer (NK)/ natural killer T (NKT) cells, and also neutrophils. (16, 17) CEACAM1 can be expressed as a long (L) and short (S) isoform. CEACAM1L contains two intracytoplasmic immune-receptor tyrosine-based inhibition motifs (ITIMs), which bind to the Src-homology 2 domain (SH2)-containing (SHP) tyrosine phosphatase, SHP1, after T-cell activation. (18) Consequently, CEACAM1L suppresses T-cell receptor activation, inflammatory cytokine production, and T-cell cytolytic function. (19) (20) (21) (22) In contrast, CEACAM1S, lacking the ITIMs, can act as an independent T-cell activator and regulator of T-cell subsets in the intestine. (19, 23) Activation of T-cell-associated CEACAM1S, or its forced overexpression in T lymphocytes, improves disease outcome in a mouse infection model, but also induces Treg subpopulations in mesenteric lymph nodes, indicating that CEACAM1 is a dichotomous regulator of immune responses in the gut. (21, 23, 24) In the mouse model of immune cell-mediated hepatic injury provoked by concanavalin A (ConA) injection, liver damage is mediated by hyperactivation of CD4 1 T cells, NKT cells, and Kupffer cells and their release of proinflammatory cytokines, such as interferon-gamma (IFNc), tumor necrosis factor alpha (TNFa), and IL-17. (25) (26) (27) The ConA model shares immunepathological features with human AIH, that is, the importance of CD4 1 T cells for liver injury, genetic association with susceptibility, and features of immunosuppression in a state of remission. (25, 28) The critical, but dichotomous, role of CEACAM1 and its isoforms in the regulation of T-cell function (18) and subsets prompted us to investigate the role of CEACAM1 in ConA-induced CD4
1 T-cell-mediated hepatitis and in human hepatic T cells. In mice, we demonstrate that CEACAM1 deficiency leads to exacerbation and prolongation of immune-mediated liver injury. Predominant CEACAM1S expression prevented CD4 1 T-cell hyperactivation, promoted IL-2-dependent STAT5 signalling in CD4 1 T cells, and stimulated induction and expansion of CD4 1 Foxp3 1 Tregs. Thus, our data suggest that CEACAM1 is an immune regulator that controls Treg homeostasis in the liver through expression of the T-cell activatory isoform, CEACAM1S, on intrahepatic T cells in mice. Moreover, we could find expression of both CEACAM1 isoforms in human liver-derived T cells from patients with inflammatory liver disease (e.g., AIH/PBC/HCV [hepatitis C virus]), indicating that similar regulatory mechanisms may be operational in human T cells.
Materials and Methods

MICE
Male 7-to 12-week-old C57BL/6 (wild type; WT), Ceacam1-deficient mice (Ceacam1 
HUMAN SPECIMEN AND ETHICS STATEMENT
Liver-infiltrating lymphocytes (LILs) were isolated from cultures of human liver biopsies or secondary liver tumors. Two methods were used: Either LILs were allowed to emigrate from liver tissues or liver tissues from the peripheral zone of secondary liver tumors were hashed. Ethics commission approvals PV4081 and PV4898 were granted by the Ethics Committee of the Hamburg Physicians Chamber. Expanded methods are detailed in the Supporting Methods section.
ConA HEPATITIS, SAMPLING OF MATERIAL, ALANINE AMIINOTRANSFERASE, AND CYTOKINE QUANTIFICATION
ConA type IV (ConA; Sigma-Aldrich, Munich, Germany) was administered intravenously (3-7 mg/kg), and blood, tissues, and cells were harvested as described. (30) Alanine aminotransferase (ALT) measurements and sandwich enzyme-linked immunosorbent assays for IL-2, IFNc, TNFa, IL-6, and IL-10 were performed as described. (31) 
ISOLATION OF NONPARENCHYMAL LIVER CELLS
Nonparenchymal liver cells (NPCs) were isolated according to Erhardt et al. (32) and restimulated with phorbol myristate acetate and ionomycin. (30) 
FLUORESCENCE-ACTIVATED CELL SORTING
Leukocytes were stained with antibodies and reagents detailed in Supporting Isolation-Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and differentiated into T-helper 1 (Th1)-polarized cells in complete RPMI-1640 medium (supplemented with 10% heatinactivated fetal bovine serum, 2 mM of Glutamax-I, 0.005% b-mercaptoethanol, and 100 U/mL of penicillin/streptomycin; all from Thermo Fisher Scientific/Invitrogen Life Technologies, Waltham, MA) as described. (33) Th1 cell polarization was achieved with a cocktail of anti-IL-4 antibodies (BioLegend) and recombinant IL-12 (R&D Systems, Minneapolis, MN).
HISTOLOGY
Murine liver biopsies were processed in routine paraffin embedding and subsequent histology with hematoxylin and eosin (H&E) stainings. Binding of anti-Foxp3 antibodies was visualized using a PolAP Kit (Zytochem, Zytomed, Berlin, Germany). (10) ADOPTIVE TRANSFER OF CD4
1
T CELLS AND Tregs
A combined sorting procedure was carried out using magnetic bead separation (CD4 1 T-Cell-negative Isolation Kit, mouse; Miltenyi Biotec) and fluorescence-activated cell sorting (FACS; BDAriaIIIu, BD Biosciences). Briefly, CD4
1 T cells were enriched using a biotinylated antibody cocktail. CD4
1 CD25 high T cells were isolated by positive selection using anti-CD25 and anti-CD4 monoclonal antibody (mAb) by FACS. 6 splenic CD4 1 T cells were injected intravenously (in PBS) into each recipient after combined MACS and FACS enrichment (as described above). Two weeks after T-cell transfer, Rag1 2/2 mice were treated with 3 mg/kg of ConA.
SUPPRESSION OF Tconv PROLIFERATION BY Tregs
T cells were enriched by combined MACS and FACS sorting (FACSAriaIIIu Cell sorting system; BD Biosciences). (32) T CELL/HEPATOCYTE COCULTURES T cells and hepatocytes were isolated and cultured as described.
(10) For a detailed description, refer to the Supporting Methods section.
DETECTION OF STAT5 PHOSPHORYLATION
Splenic single-cell suspensions from ConA-treated mice were either directly subjected to phosphorylated STAT5 (pSTAT5) labeling, or NPCs from livers were isolated and restimulated before pSTAT5 labeling in T cells. (30) Detailed procedures for pSTAT5 labeling are described in Chen et al. (5) 
RNA ISOLATION AND qRT-PCR AND SEMIQUANTITATIVE RT-PCR
RNA from human and murine T cells was isolated using a Quiagen RNAeasy micro/mini isolation kit (Quiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription was performed with the Verso complementary DNA (cDNA) synthesis kit (Thermo Fisher Scientific/Invitrogen Life Sciences). Primers and expanded methods are given in the Supporting Methods section.
STATISTICAL ANALYSES
Data are presented as mean values 6 SEM. Results were analyzed with a Student t test (two groups) or analysis of variance (>2 groups) using Prism software (versions 5.0 and 7.0; GraphPad Software). Significant differences between groups are represented by *P 0.05, **P 0.01, and ***P 0.001.
Results
AGGRAVATED AND PERSISTING LIVER DAMAGE IN Ceacam1
2/2
MICE AFTER ConA TREATMENT
To investigate whether CEACAM1 has a regulatory role in immune-mediated liver injury, Ceacam1 2/2 and WT mice were treated with a single intravenous injection of ConA and liver injury was measured by plasma ALT activities. Under homeostatic conditions, absence of CEACAM1 neither influences ALT levels ( Fig.  1A ) nor overall cell yields of primary hepatocytes isolated from either mouse strain (not shown), nor viability of the hepatocytes (Supporting Fig. S1A ,B) Also, hepatocytes from either genotype were equally sensitive toward TNFa-induced cell death in vitro (Supporting Fig. S1C ). However, application of ConA resulted in exacerbation of liver damage in Ceacam1 2/2 mice compared to WT mice ( Fig. 1B-D) , yielding significantly higher ALT levels 24 and 48 hours after ConA treatment (Fig. 1C,D) . Histological examination revealed extensive necroinflammatory areas in CEACAM1 2/2 livers ( Fig. 1E ), but not in WT livers. Interestingly, plasma levels of IL-2 ( Fig. 2A) were significantly lower in Ceacam1 2/2 mice 2 hours after ConA application compared to WT mice. Additionally, intrahepatic Il-2 mRNA levels were significantly reduced 8 hours after ConA administration in Ceacam1 2/2 mice (Fig. 2B ). However, we detected comparable plasma levels of IFNc, TNFa, IL-6, and IL-10 in Ceacam1 2/2 mice and WT controls (Supporting Fig. S2A-D) , indicating that rather the reduction of IL-2 production than the early cytokine storm was responsible for aggravation of liver injury in Ceacam1 2/2 mice.
Ceacam1 DEFICIENCY RESULTS IN POOR IL-2 PRODUCTION BY CD4 1 T CELLS AND CORRELATES WITH A LOSS OF THE CEACAM1S ISOFORM
Because Tregs require IL-2 for their expansion, suppressor function, and survival, (34) and substantially dampen ConA-induced liver injury, (31) we analyzed the impact of Ceacam1 deficiency on the potential of CD4 (Supporting Fig. S3A ), but significantly reduced production of IL-2 per cell (Supporting Fig. S3B ), upon in vitro restimulation in CEACAM1 (Fig. 2C) , as well as lower amounts of IL-2 per cell compared to WT controls (Fig.  2D) . The reduced ability of CEACAM1 2/2 CD4 1 T cells to produce IL-2 points to an inhibition of T-cell receptor activation in these cells. This might be attributed to isoform-specific expression of CEACAM1 in CD4 1 T-cell clones from LILs from human diagnostic biopsies, with the diagnosis and respective CEACAM1 isoforms ("L" for CEACAM1L, "S" for CEACAM1S, as indicated); "alc.tox. HCV in rem.": patient with alcohol toxic hepatitis and hepatitis C infection in remission. cDNAs for CEACAM1S/CEACAM1L were used as controls. CEACAM1-4L, CEACAM1-4S and CEACAM1-3L/CEACAM1-3S represent CEACAM1 isoforms with four and three extracellular domains. (17, 39) The amplicon sizes for the respective isoforms are indicated. Data, mean 6 SEM; P 0.05; **P 0.01; ***P 0.001. Abbreviations: bp, base pair; MFI, mean fluorescent intensity; n.d., not detected.
T cells. CEACAM1S is known to elicit T-cell activation by induction of nuclear factor of activated T cells (NFAT)-mediated transcription of genes such as Il-2. (23) Isoform-specific RT-PCR revealed that na€ ıve intrahepatic CD4 1
CD25
-and CD4 1 CD25 -T cells also seem to up-regulate the inhibitory Ceacam1L isoform, but also prominently coexpress Ceacam1S (Fig.  2E) . Interestingly, numbers of CEACAM1 1 hepatic CD4
1 T cells were significantly induced 24 hours after ConA injection to WT mice (Supporting Fig. S4 ), indicating a sustained ability of WT CD4
1 T cells to produce IL-2, which might be necessary for sufficient Treg induction. We further analyzed human liver-derived CD4
1 T cell clones isolated from diagnostic biopsies of patients with AIH, overlapping AIH/PBC, and 1 patient with alcoholic hepatitis/HCV in remission (Fig. 2F) . Human CEACAM1 exists in four isoforms with either three or four extracellular domains and either a long or a short intracellular domain (CEACAM1-3L/S and CEACAM1-4L/S). This differs from mice in which the three domain forms are not expressed. (17) The CEA-CAM1-3L/4L and -3S/4S isoforms are believed to function similarly in terms of T-cell activation or inhibition. (18) In T cells from patients with active AIH/ PBC or alcoholic hepatitis and HCV in remission, both CEACAM1-4L and CEACAM1-4S were detected. These patients still exhibit considerable elevation of ALT and aspartate aminotransferase activities in their plasma (patient details: Supporting Table S3 ). Additionally, CEACAM1-3L and CEACAM1-3S were expressed, albeit at lower levels. Moreover, we analyzed CEACAM1 expression in human CD4 S5 ), indicating that expression of both CEACAM1 isoforms correlates with inflammatory liver disease and probably disease activity. (Fig. 3A,B) . However, the magnitude of expansion was significantly lower in Ceacam1 2/2 mice (WT 3-fold, Ceacam1 2/2 2-fold induction; Fig. 3B ). Similar results were obtained after quantification of Foxp3 1 cells in liver sections of ConA-treated mice that were stained in immune histochemistry (Fig. 3C,D) , indicating that Treg induction after ConA exposure is impaired in the absence of CEACAM1. Furthermore, we stained CD4
Foxp3
1 cells for the antiapoptotic protein, B-cell lymphoma 2 (Bcl-2; Fig. 3E ), which revealed significantly higher endogenous levels of Bcl-2 in WT versus 
CD4
1 T cells did not survive the first 8 hours after ConA treatment (Fig. 4A) . H&E staining of liver sections showed severe hepatic necroses with large bridging areas in recipients of CEACAM1 
CD62L
-CD4 1 T cells. Data, mean 6 SEM, n 5 6; *P 0.05.
CD4
1 T cells, but less necrosis after transfer of WT cells (Fig. 4B) . Analyzing the composition of hepatic CD4 1 T cells from these mice, we found that frequencies of proliferating Ki67 1 CD4 1 T cells were significantly elevated in transferred CEACAM1 2/2
1 T cells compared to the WT CD4 1 T cells (Fig. 4C) . Additionally, within the Ki-67 1
1 T cells, there was a trend toward more activated CD44 
CD62L
cells under Ceacam1 deficiency (Fig. 4D) . In sharp contrast, the CD4 1 Foxp3 1 population was greatly reduced in Ceacam1 2/2 compared to WT CD4 1 T cells (Fig.  5A) . Moreover, the fraction of Foxp3 1 cells within the proliferating Ki-67 1 CD4 1 cell cluster was significantly reduced in the CEACAM1 2/2 donor CD4 1 population (Fig. 5B) . However, the proportion of proliferating Ki-67 
CD4
1 T cells was not affected by Ceacam1 deficiency (Fig. 5C ). This indicates that CD4 1 T-cell conversion toward Tregs and/or their stability rather than their proliferation is impaired in Ceacam1 Tregs from both WT and Ceacam1 2/2 mice that were treated 8 days before with ConA ("ConA-primed" Tregs (31) ) equally suppressed Tconv at a 1:1 ratio (Fig.  6A) . We used ConA-primed Tregs, which contain 98% Foxp3
1 Tregs, because we have previously shown that they significantly protect WT mice from ConAinduced liver injury in contrast to na€ ıve Tregs. (31) However, using a 1:4 ratio of Tregs to Tconv, we observed a slight, but significant, reduction of in vitro suppression by CEACAM1 
CD25
high T cells protected mice from liver injury (Fig. 6B) . In marked contrast, adoptive transfer of CEACAM1 2/2
CD4
1 CD25 high T cells provoked 50% lethality within 8 hours after ConA injection. To describe the overall adverse effects of ConA liver injury, we defined a ConA-damage score based on ALT levels and overall survival (Fig. 6C) . This damage score illustrates that adoptive transfer of CEACAM1 2/2 CD4 1 CD25 high T cells fails to protect from liver damage (Fig. 6C) . In order to determine putative differences of cytokine production by the transferred cells from both genotypes, we analyzed the cytokine profile (Ifnc, Il-17, Tgfb, or Il-10) of sorted splenic WT or CEACAM1
2/2 CD4 1 CD25 high T cells and did not find any significant difference (Supporting Fig. S6A-D (Fig. 6D) as well as cellular expression levels of CD25 (Fig. 6E) were 
Foxp3
1 Tregs of WT and Ceacam1 2/2 mice (n 5 6). Data, mean 6 SEM; *P 0.05; **P 0.01. Abbreviation: MFI, mean fluorescent intensity. significantly higher in WT opposed to CEACAM1 2/ 2 donors. In summary, these data suggest that in the absence of CEACAM1, ConA application fails to induce stable Tregs sufficient to regulate and protect from immune-mediated hepatitis.
IMPAIRED Treg CONVERSION IN THE ABSENCE OF CEACAM1
So far, our data suggest that Treg induction or stability is affected in vivo if CEACAM1 is absent in CD4 1 T cells and Tregs. Therefore, the capacity of Tconv to convert into Tregs was tested in cocultures of na€ ıve CD4 1 T cells with hepatocytes in the presence of TGFb, which potently induces Foxp3 1 Tregs. (10) Expectedly, efficient CD4 
Foxp3
1 Treg induction in the absence of hepatocytes was approximately 0.6 6 0.2%. Contrarily, Treg conversion from CEACAM1 2/2 CD4 1 T cells by hepatocytes was reduced to almost half (Fig. 7A) . Not only the conversion efficacy, but also Foxp3 levels per cell were significantly reduced in the absence of CEACAM1 (Fig.  7B) . Because autocrine IL-2-mediated signaling is important for the stable expression of Foxp3, (12) we quantified IL-2 in cocultures of CD4
1 Tconv and hepatocytes. There was a tendency toward less IL-2 production in cocultures with CEACAM1 (Fig. 7C) , indicating that even a slight reduction of IL-2 concentrations could reduce Treg conversion in the absence of CEACAM1. This is also corroborated by our findings that plasma and intrahepatic IL-2 levels were significantly reduced after ConA challenge in Ceacam1 2/2 mice in vivo ( Fig. 2A,B) .
STAT5 PHOSPHORYLATION IS IMPAIRED IN THE ABSENCE OF CEACAM1
To further elucidate CEACAM1-mediated mechanisms that influence Treg conversion and homeostasis, we analyzed IL-2-mediated signaling in CD4 1 T cells from both mouse lines. Two hours after ConA treatment, numbers of pSTAT5-expressing T cells (Fig.  8A ) as well as their cellular pSTAT5 expression levels ( 
CD4
1 T cells as well as cellular pSTAT5 expression levels were observed 24 hours after ConA challenge in Ceacam1 2/2 mice (Fig.  8C, D) . These data indicate that the response of T cells from Ceacam1 2/2 mice to IL-2 is blunted. Consequently, STAT5 phosphorylation, which is essential for Treg function and stability, (12) is not observed in T cells from Ceacam1 2/2 mice. Our findings strongly point toward an active role of CEACAM1S in the positive regulation of IL-2 signaling.
Discussion
In this report, we analyzed the role of the immune regulator, CEACAM1, in a murine model of acute immune-mediated liver injury and observed that it promotes IL-2-mediated signaling in CD4 1 T cells, Treg induction, and Treg stability. The importance of IL-2 for the survival and suppressive function of Tregs in patients with autoimmune liver diseases has been highlighted recently. (5) Tregs constitutively express the high-affinity receptor for IL-2 (CD25; IL-2Ra), which enables IL-2 to control Treg homeostasis by STAT5-mediated signaling. (4) pSTAT5 induces upregulation of Foxp3 and CD25 expression and is critical for Treg survival, stability, and their CTLA-4-dependent function in autoimmune liver diseases. (4, 35) Contrary to Tregs, Tconv require significantly higher IL-2 concentrations to induce their proliferation. (36) Recently, insufficient IL-2 availability was identified as a central cause for decreased Treg effectivity in patients with hepatic autoimmune diseases. (4) However, few data are available on coimmune receptors that directly modulate IL-2 production and IL-2-mediated signaling. In our report, we show that Ceacam1 controls hepatic Treg homeostasis by induction of IL-2 production, stimulation of IL-2 signaling, and induction of Foxp3 and CD25 expression.
First, we observed exacerbation and persistence of ConA-mediated hepatitis in Ceacam1 2/2 mice. Second, characterization of the CD4 
Foxp3
1 Treg conversion in combination with a tendency toward reduced IL-2 production was observed in anti-CD3 mAb-stimulated cocultures of CEACAM1 2/2
CD4
1 T cells and WT hepatocytes, which are likely to provide the homophilic ligand in trans (17) for Ceacam1 expressed by WT CD4 1 T cells. These data are reminiscent of the disruption of the IL-2/Treg axis and inappropriate Tconv hyperactivation observed by others in systemic lupus erythematosus (SLE) or rheumatoid arthritis. (37, 38) Importantly, recent reports documented that modulating the Tconv/Treg ratio by Aldesleukin/Proleukin has proven successful in the treatment of SLE and patients with autoimmune liver disease. (4, 38) By administration of low-dose IL-2, the progressive dysbalance between Treg and Tconv can be alleviated, along with restoring CD25 expression levels on dysfunctional Tregs in SLE, as well as stabilizing functional Treg marker expression (CD25, Bcl-2, Foxp3, and CTLA-4) in peripheral Tregs of patients with AIH, PBC, or PSC. (4, 38) Accordingly, we revealed a dysbalance in Tconv and Treg expansion in Ceacam1 2/2 mice, accompanied by reduction of IL-2 production in CEACAM1 Fig. 3E ).
Because CEACAM1
1
CD4
1 CD25 high cells appear to display specific functional features that are mediated by CEACAM1-induced signaling in Tregs, we characterized the isoform expression pattern of intrahepatic CD4 1 T cells (see Fig. 2 ). Our data described so far point toward an activating role of CEACAM1 in T cells, especially with regard to their production of IL-2. It has been shown that forced overexpression of CEA-CAM1S in CD4
1 T cells stimulates activator protein 1-/NFAT1-mediated signaling, enhances NFAT1 nuclear translocation, and, subsequently, induces upregulation of NFAT1-dependent cytokines, such as IL-2. Here, we show that in both na€ ıve and ConApretreated mice, intrahepatic CD4
1 T cells and Tregs predominantly express Ceacam1S. This is reminiscent of resident T cells in the intestine that exhibit predominant expression of the CEACAM1S isoform in contrast to peripheral T cells, which predominantly express Ceacam1L. (23) As such, CEACAM1S expression on hepatic T cells may ultimately lead to activation of IL-2 production and signaling as well as to conversion into liver-resident Tregs.
We furthermore observed a slight up-regulation of the ITIM-bearing CEACAM1L isoform in CD4 
CD25
-T cells in response to ConA injection, pointing to the possibility that, during inflammation, CEA-CAM1L provides a different level of T-cell regulation. It was shown that the CEACAM1L isoform is dominant in the inhibition of T-cell activation, even if its expression relative to CEACAM1S is significantly lower. (18) Thus, we propose that the timed expression of both CEACAM1 isoforms is required to regulate T-cell subsets in liver injury: First, the CEACAM1S-isoform expressed on CD4 1 T cells ensures Treg induction and stability in a feed-forward cycle initiated by IL-2 production, and, second, exacerbation of inflammation/hyperactivation of Tconv is counterbalanced by up-regulation of CEACAM1L (Supporting Fig. S7A,B) . In addition to our mouse model, we analyzed the expression of human CEACAM1 and its corresponding isoforms on T-cell clones derived from intrahepatic compartments (Fig. 2F and Supporting  Fig. S6 ). Both isoforms are detectable in CD4
1 Tcells clones from AIH and PBC patients, as well as from a patient with alcohol toxic hepatitis/HCV infection in remission (Fig. 2F) . In contrast, only very low levels of CEACAM1L expression were detected in CD4 1 CD25 -Tconv, but not CD4
1
CD25
1 T cells, from a patient with a secondary liver tumor (Supporting Fig. S6 ). These findings may reflect that both isoforms can be induced in chronic human autoimmune liver diseases. On the other hand, it has been reported that the dominant expression of CEACAM1S by tissue resident T cells is lost under ex vivo culture conditions. (23) This underscores the importance of the local tissue micromileu for the induction and maintenance of CEACAM1 isoform expression.
In summary, we identified CEACAM1 as a regulator of local immune response in the liver, whereby CEACAM1S seems to control Treg induction. Based on our results, we propose a model for CEACAM1 involvement in Treg conversion and stability (Supporting Fig. S7 ): First, CEACAM1S
1
CD4
1 T cells show increased IL-2 production (Supporting Fig. S7A ), based on enhanced NFAT1 transcriptional activity; furthermore, this increase in IL-2 production stimulates STAT5 phosphorylation through the IL-2R complex, leading to enhanced transcription of key functional Treg genes (Cd25, Foxp3, and Bcl-2; Supporting Fig. S7B ). In this way, CEACAM1S supports self-sustainment of IL-2-mediated signaling that is required for Treg homeostasis. Further studies will be necessary to investigate whether CEACAM1 binding tools can be utilized as a therapeutic approach for the treatment of autoimmune liver diseases by supporting Treg expansion and stability.
